Perrigo has announced that its partner, Cobrek Pharmaceuticals Inc., has received final approval from the U.S. Food and Drug Administration for its generic equivalent to Luxiq, a foam treatment for scalp psoriasis, with Perrigo now set to begin commercial shipments of it in mid January.

Perrigo, based in Allegan, has been in a product development partnership with Cobrek since buying a stake in the company in 2008. Cobrek is in Chicago and is a division of Pentech Pharmaceuticals of Rolling Meadows, Ill.

The Luxiq brand has had annual sales of about $40 million, prior to the expiration of the patent on it. Cobrek was the first company to file for production of the generic version and will have 180 days to market it exclusively with Perrigo.

“This is our sixth product approval using a foam dosage form, which requires specialized development and manufacturing capabilities,” said Joseph C. Papa, Perrigo chairman, president and CEO. “It is an example of the excellent partnership we have with Cobrek and we are committed to making quality health care more affordable for our customers and drive value for our shareholders.”